Jim Simons
TCRX icon

Jim Simons’s TScan Therapeutics TCRX Stock Holding History

Jim Simons’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.38M Buy
1,364,783
+223,714
+20% +$239K ﹤0.01% 2101
2025
Q4 		$1.14M Buy
1,141,069
+311,150
+37% +$450K ﹤0.01% 2201
2025
Q3 		$1.51M Buy
829,919
+37,863
+5% +$67.1K ﹤0.01% 2251
2025
Q2 		$1.15M Buy
792,056
+622,350
+367% +$899K ﹤0.01% 2434
2025
Q1 		$234K Buy
169,706
+159,106
+1,501% +$344K ﹤0.01% 3027
2024
Q4 		$32.2K Sell
10,600
-63,400
-86% -$287K ﹤0.01% 3444
2024
Q3 		$369K Sell
74,000
-6,000
-8% -$36.2K ﹤0.01% 2902
2024
Q2 		$468K Buy
80,000
+33,000
+70% +$260K ﹤0.01% 2718
2024
Q1 		$373K Buy
47,000
+25,300
+117% +$159K ﹤0.01% 2993
2023
Q4 		$127K Buy
21,700
+4,000
+23% +$18.3K ﹤0.01% 3243
2023
Q3 		$45K Sell
17,700
-129,762
-88% -$303K ﹤0.01% 3421
2023
Q2 		$369K Buy
147,462
+135,862
+1,171% +$364K ﹤0.01% 3032
2023
Q1 		$24K Buy
11,600
+1,600
+16% +$3.8K ﹤0.01% 3796
2022
Q4 		$16K Buy
+10,000
New +$24.5K ﹤0.01% 3996
2022
Q2 		– Sell
-13,300
Closed -$37K – 4567
2022
Q1 		$37K Buy
+13,300
New +$57.5K ﹤0.01% 3948

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Jim Simons's TCRX Position: Q1 2026 in Review

Jim Simons increased its TScan Therapeutics (TCRX) stake by 20% in Q1 2026, buying an estimated $239K and bringing the position to 1,364,783 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2101.

Jim Simons first reported a position in TCRX in Q1 2022 and has held it in 15 quarters since. The position peaked at $1.51M in Q3 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Jim Simons held 1,364,783 shares of TScan Therapeutics worth $1.38M as of Q1 2026.
  • Jim Simons bought 223,714 TScan Therapeutics shares in Q1 2026, an estimated $239K.
  • TScan Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2101 holding.
  • Jim Simons first reported a position in TScan Therapeutics in Q1 2022 and has held it in 15 quarters since.
  • Jim Simons's TScan Therapeutics position peaked at $1.51M in Q3 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.